Sonja Loges: My highlights from WCLC23 so far.

Sonja Loges, Director, W3 Professor, Department of Personalized Oncology & DKFZ-Hector Cancer Institute, University Medical Center Mannheim/German Cancer Research Center (DKFZ), Heidelberg, made the following post on LinkedIn:

“My highlights from WCLC23 so far:

MARS-2 demonstrates inferior survival upon perioperative chemo with radical decortication pleurectomy in mesothelioma compared to chemotherapy alone. Practice-changing data in my opinion – looking forward to discussion with thoracic surgeons.

Long awaited FLAURA-2 data (osimertinib plus chemotherapy including Pem maintenance vs. osimertinib alone) leave me with a mixed bag of thoughts. 10 mo difference in terms of PFS at the cost of 44% severe tox (G3, G4) – OS curves not mature, do not look impressive. Efficacy high in patients with Exon21 mut and mets.

“Tsunami“ of ADCS targeting HER2, TROP2, HER3, MET, CEACAM5…. Puzzling is the lack of biomarker/lacking association with in many of them. Either very little target suffices or some effects are unspecific.. Too early to sort their positioning in treatment landscape..”

Source: Sonja Loges / LinkedIn